Refining T cell biology to develop powerful biologics
![](https://t-therapeutics.com/wp-content/uploads/2023/11/T-Cell_Science_B.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/10/T-T_P_HC.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/TCR2.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Healthy_Human_Cell.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/T-Cell-Bad-Cell.png)
Scroll Down
T Cell Biology
T cells are a type of white blood cell that are an essential part of your immune system and play a central role in the adaptive immune response.
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Unhealthy_Human_Cell_L.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Unhealthy_Human_Cell_OL.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/T-Cell_L.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/10/t-cell-bind-300x61.png)
One type of T cell acts as ‘killer cells’, attacking cells infected by a virus or other pathogen which they recognise through fragments of foreign proteins (antigens) displayed on the surface of these cells.
Once the threat has gone, these T cells become dormant. Some will remain as memory cells for many years: if the threat returns, your immune system can recognise it and fight it off quickly.
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Unhealthy_Human_Cell_MHCs.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/10/T-T_P_HC.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/t-cell-blur-back.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Healthy_Human_Cell-blur.png)
Scroll Down
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Cancer_Cell_Blur.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Cancer_Cell_M.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Cancer_Cell_O.png)
T cells play an important role in fighting cancer.
A normal cell transforms into a cancer cell through a series of mutations in its DNA. These result in changes to the protein fragments displayed on the surface of the cancer cell.
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Cancer_Cell_MHCs.png)
Mutated protein fragments, known as neoantigens, can be recognised by T cells but most of the fragments – although cancer specific – are not recognised.
These fragments are derived from genes which are re-expressed in the cancer cell and recognised as “self”. Owing to this process, tumours are able to evade the immune system to grow and spread.
![](https://t-therapeutics.com/wp-content/uploads/2023/11/T-Cell_Cancer_Cell.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/T-Cell_Cancer_Cell_T.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/T-Cell_Cancer_Cell_O.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/T-Cell_Cancer_Cell_MHCs.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Cancer-bind-t-blur.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Cancer-bind-c-blur.png)
Scroll Down
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Cancer_Inspect_G.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Cancer_Inspect_Cells.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Cancer_Inspect_O.png)
The part of the T cell that binds to a foreign antigen or cancer neoantigen is called the T cell receptor (TCR). It is this binding of the TCR to an antigen that causes T cell activation, proliferation and differentiation.
Advances in our understanding of T cell biology have enabled the development of immuno-oncology drugs such as check point inhibitors. These work by stimulating the response to cancer neo-antigens but they are unable to overcome the inability to recognise the cancer-specific “self” antigens.
The approach we are using to target cancer cells is also being developed for autoimmune conditions – although in this case we are aiming to suppress inflammation in a highly specific manner.
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Cancer_Inspect_Bind.png)
T-Therapeutics is developing drugs which can recognise these self-antigens and re-direct T cells to kill these cancer cells.
![](https://t-therapeutics.com/wp-content/uploads/2023/10/t-cell-bind.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Cancer-attack-t-blur.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Cancer-attack-c-blur.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Cancer-death-t-cell.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/Cancer-death-c-cell.png)
Scroll Down
![](https://t-therapeutics.com/wp-content/uploads/2023/11/OpTiMus_T_Icon_B.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/OpTiMus_T_Protein_B.png)
![](https://t-therapeutics.com/wp-content/uploads/2023/11/OpTiMus_T_Graphic_B.png)
Our Platform
Best-in-class transgenic mouse platform combined with disease-to-target discovery approach.
![](https://t-therapeutics.com/wp-content/uploads/2023/10/t-cell-bind.png)
Our goal is to treat cancers that are currently untreatable – reshaping the clinical landscape for cancer patients.
Prof. Allan Bradley FRS, FMedSci
Chief Executive Officer
![](https://t-therapeutics.com/wp-content/uploads/2023/10/T-Therapeutics_icon-footer-150x150.png)